A recent article in Popular Information tries to cast Secretary Robert F. Kennedy Jr., the Trump administration, and critics of psychiatric overprescribing as reckless zealots. That narrative is politically convenient, but it is not an honest description of what the U.S. Department of Health and Human Services has actually announced.

The truth is more important than the rhetoric. Americans are being asked to believe that any serious scrutiny of psychiatric drug use is inherently dangerous, when in fact HHS has said it is pursuing a patient-centered approach built on informed consent, shared decision-making, prevention, transparency, and greater use of non-drug options where clinically appropriate.

That is not extremism. That is overdue reform.

What the Administration Is Actually Doing

In May 2026, HHS launched a MAHA Action Plan to curb psychiatric overprescribing. According to HHS and related coverage quoting the agency’s language, the effort is intended to evaluate prescribing patterns, assess benefits and potential harms, prevent unnecessary initiation of psychiatric drugs, and support tapering or discontinuation for individuals not experiencing clinical benefit.

HHS has also said the plan will support patient autonomy, require informed consent and shared decision-making, and shift the standard of care toward prevention, transparency, and a more holistic approach to mental health. The agency specifically identified family support, nutrition, and physical activity as nondrug approaches that should play a larger role.

That matters because the debate should not be caricatured as “medication versus no medication.” The real issue is whether Americans are getting full disclosure of risks and benefits, whether safer or less invasive options are being overlooked, and whether patients and families are truly free to make informed choices.

Why This Is Good for Americans

The Trump administration’s MAHA framework did not emerge in a vacuum. President Trump established the MAHA Commission in February 2025 and charged it with confronting rising rates of mental health labeling and chronic health problems while emphasizing prevention, root causes, transparency, and open data in federally funded research.

That approach is good for Americans because it asks questions that the healthcare system has too often avoided. Why are psychiatric drugs being prescribed in such high numbers? Why are children being placed on potentially dangerous drugs? Are patients truly being fully informed about adverse effects, withdrawal difficulties, and effective nondrug alternatives?

A health system that encourages these questions is more accountable. A mental health system that values informed consent, non-drug interventions, family support, and deprescribing is not taking anything away from Americans; it is giving them more information, more options, and more protection.

The Problem With the Article’s Framing

The Popular Information piece uses a familiar strategy: shift the focus away from the substance of policy and toward association-based attacks. Its central message is that because it objects to Kennedy’s past statements the administration’s current policies should be dismissed as dangerous by definition.

But that is not how serious policy analysis works. The relevant question is not whether critics are unpopular in elite media circles. The relevant question is what HHS has actually put in writing and whether those actions would improve transparency, patient choice, and access to alternatives.

On that question, the administration’s position is clear. HHS is not announcing a ban on antidepressants or a blanket prohibition on psychiatric care. It is calling for stronger review of prescribing practices, fuller disclosure, and support for nondrug care alongside tapering for those who want off drugs.

Mental Health Policy Should Put People First

For too long, Americans have been told that questioning psychiatric labels and drugs is irresponsible. The actions now being taken treat those questions as legitimate, moving federal policy toward informed consent, shared decision-making, prevention, and proven non-drug options.

That is why the actions now being taken by HHS, Secretary Kennedy, and the Trump administration deserve a fair hearing. They are moving the country toward a more transparent, preventive, and people-protective framework. In a healthcare culture where questioning the medicalization of everyday human behavior and normal reactions to adverse events in life is often treated as taboo, that is not something to push back against. It is something to welcome.